EA200200802A1 - 5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ - Google Patents

5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ

Info

Publication number
EA200200802A1
EA200200802A1 EA200200802A EA200200802A EA200200802A1 EA 200200802 A1 EA200200802 A1 EA 200200802A1 EA 200200802 A EA200200802 A EA 200200802A EA 200200802 A EA200200802 A EA 200200802A EA 200200802 A1 EA200200802 A1 EA 200200802A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sor
cor
compounds
hydrogen
lower alkyl
Prior art date
Application number
EA200200802A
Other languages
English (en)
Inventor
Ричард Джон Бут
Эллен Майра Добрусин
Питер Лоренс Тугуд
Скотт Норман Вандеуэл
Original Assignee
Уорнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани filed Critical Уорнер-Ламберт Компани
Publication of EA200200802A1 publication Critical patent/EA200200802A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описаны соединения формулы I, где Rпредставляет собой водород, алкил или циклоалкил; Rпредставляет собой водород, низший алкил, низшую алкоксигруппу, галоген, трифторметил, низший алкинил, низший алкенил, нитрил, нитрогруппу, -COR, -COR, -CONRR, -CONROR, -SONRR, -SOR, -SOR, (формулу (II)) или -NRR; Y представляет собой N или CR; Rпредставляет собой низший алкил, галогеналкил или арил; Х и Z независимо представляют собой водород, галоген, низший алкил, низшую алкоксигруппу, трифторметил, гидроксигруппу, нитрил, нитрогруппу, -NRR, -N(O)RR, -NRRRW, -SR, -C(O)R, -COR, -CONRR, -SONRR, -SOR, -SOR, P(O)(OR)(OR), -T(CH)QR, -C(O)T(CH)QRили -NRC(O)T(CH)QR; m является числом от 1 до 6. Эти соединения можно применять для лечения пролиферативных заболеваний клеток, таких как рак, атеросклероз и повторный стеноз. Эти соединения являются сильными ингибиторами циклинзависимых киназ (cdks) и киназ, опосредованных фактором роста.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200802A 2000-03-06 2001-01-29 5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ EA200200802A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EA200200802A1 true EA200200802A1 (ru) 2003-02-27

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200802A EA200200802A1 (ru) 2000-03-06 2001-01-29 5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ

Country Status (37)

Country Link
EP (1) EP1268476A1 (ru)
JP (1) JP2003528101A (ru)
KR (1) KR20020075805A (ru)
CN (1) CN1422268A (ru)
AP (1) AP2002002643A0 (ru)
AR (1) AR034119A1 (ru)
AU (1) AU2001233028A1 (ru)
BG (1) BG107161A (ru)
BR (1) BR0109056A (ru)
CA (1) CA2401368A1 (ru)
CO (1) CO5280200A1 (ru)
CR (1) CR6736A (ru)
CZ (1) CZ20022929A3 (ru)
DZ (1) DZ3308A1 (ru)
EA (1) EA200200802A1 (ru)
EE (1) EE200200506A (ru)
GT (1) GT200100037A (ru)
HN (1) HN2001000040A (ru)
HR (1) HRP20020798A2 (ru)
HU (1) HUP0300136A2 (ru)
IL (1) IL151480A0 (ru)
IS (1) IS6524A (ru)
MA (1) MA26881A1 (ru)
MX (1) MXPA02008535A (ru)
NO (1) NO20024235L (ru)
NZ (1) NZ520962A (ru)
OA (1) OA12227A (ru)
PA (1) PA8513201A1 (ru)
PE (1) PE20011177A1 (ru)
PL (1) PL358271A1 (ru)
PY (1) PY0104899A (ru)
SK (1) SK12472002A3 (ru)
SV (1) SV2001000338A (ru)
TN (1) TNSN01036A1 (ru)
WO (1) WO2001070741A1 (ru)
YU (1) YU66502A (ru)
ZA (1) ZA200207110B (ru)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de) 2000-10-23 2011-09-15 Glaxosmithkline Llc Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
DE60206363T2 (de) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
MXPA03007623A (es) * 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
EP1408985A4 (en) * 2001-06-21 2006-03-22 Ariad Pharma Inc NEW PYRIDOPYRIMIDONE AND ITS USES
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ATE412650T1 (de) * 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
WO2006110298A2 (en) 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
DK2074122T5 (da) 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2137184B1 (en) * 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ES2608940T3 (es) * 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (ja) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
CA2807498C (en) * 2010-08-05 2017-02-07 Temple University-Of The Commonwealth System Of Higher Education 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
SI2958916T1 (sl) * 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
CN113166148B (zh) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
AU2022234998B2 (en) * 2021-03-08 2025-04-10 Jinan University Pyridopyrimidine compounds and applications thereof
CN116456987A (zh) * 2021-06-09 2023-07-18 郑州同源康医药有限公司 用作cdk激酶抑制剂的化合物及其应用
JP2025531320A (ja) * 2022-09-16 2025-09-19 イースト チャイナ ノーマル ユニバーシティ Ｒｓｋ阻害剤としてのピリドノピリミジン誘導体及びその応用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2301194T3 (es) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
AU763839B2 (en) * 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
SK12472002A3 (sk) 2003-04-01
PY0104899A (es) 2003-11-03
PE20011177A1 (es) 2001-11-23
MA26881A1 (fr) 2004-12-20
WO2001070741A1 (en) 2001-09-27
CR6736A (es) 2004-03-10
SV2001000338A (es) 2001-11-30
NO20024235L (no) 2002-11-05
EP1268476A1 (en) 2003-01-02
EE200200506A (et) 2004-02-16
CO5280200A1 (es) 2003-05-30
NO20024235D0 (no) 2002-09-05
AU2001233028A1 (en) 2001-10-03
MXPA02008535A (es) 2002-12-13
YU66502A (sh) 2005-09-19
TNSN01036A1 (en) 2005-11-10
AP2002002643A0 (en) 2002-12-31
AR034119A1 (es) 2004-02-04
PL358271A1 (pl) 2004-08-09
HUP0300136A2 (en) 2003-05-28
PA8513201A1 (es) 2003-06-30
GT200100037A (es) 2002-03-04
HN2001000040A (es) 2001-09-06
DZ3308A1 (fr) 2001-09-27
CZ20022929A3 (cs) 2003-02-12
IS6524A (is) 2002-08-23
JP2003528101A (ja) 2003-09-24
NZ520962A (en) 2003-09-26
BG107161A (bg) 2003-06-30
OA12227A (en) 2004-03-18
HRP20020798A2 (en) 2004-02-29
CA2401368A1 (en) 2001-09-27
BR0109056A (pt) 2003-06-03
KR20020075805A (ko) 2002-10-05
CN1422268A (zh) 2003-06-04
ZA200207110B (en) 2003-12-04
IL151480A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
EA200200802A1 (ru) 5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ
EA200200643A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-2,7-ДИАМИНОВЫЕ ИНГИБИТОРЫ КИНАЗ
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
EP1620411A4 (en) HEMMER OF ACT ACTIVITY
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
UA74370C2 (ru) Пирроло(2,3-d)пиримидиновые соединения как иммуносупрессоры
DK1123296T3 (da) Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
EA200001171A1 (ru) Бициклические пиримидины и бициклические 3,4-дигидропиримидины как ингибиторы клеточной пролиферации
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
EP1631548A4 (en) HEMMER OF ACT ACTIVITY
TR200401903T4 (tr) Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.
EA200200769A1 (ru) Ингибиторы гиразы и их применение
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
EA200300674A1 (ru) Получение гетероциклических сульфонамидных ингибиторов бета-амилоида
ATE283856T1 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
BRPI0413467A (pt) aminopironas e seu uso como inibidoras da atm
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
BRPI0407841A (pt) inibidores heterocìclicos de quinase
AR035434A1 (es) Fluoralcoxifenilsulfonilureas sustituidas, procedimiento para su preparacion, procedimiento para combatir el crecimiento indeseable de las plantas o de los microorganismos, empleo de estos compuestos para combatir el crecimiento indeseable de las plantas o de los microorganismos, agente herbicida y
ES8107142A1 (es) Un procedimiento para la preparacion de acetofenonas substi-tuidas
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas